

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Botanix Pharmaceuticals Ltd
ABN	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Vincent Ippolito
Date of last notice	9 October 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Vincent Peter Ippolito and Karen Ann Ippolito <The Ippolito Trust> - trustee and beneficiary of the trust
Date of change	10 April 2026
No. of securities held prior to change	Vincent Peter Ippolito 16,000,000 Performance Rights (expiring 2 December 2029) Vincent Peter Ippolito and Karen Ann Ippolito <The Ippolito Trust> - trustee and beneficiary of the trust 15,001,644 Fully Paid Ordinary Shares
Class	Fully Paid Ordinary Shares
Number acquired	1,666,667 Fully Paid Ordinary Shares
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.06 per Fully Paid Ordinary Share

No. of securities held after the change	Vincent Peter Ippolito 16,000,000 Performance Rights (expiring 2 December 2029) Vincent Peter Ippolito and Karen Ann Ippolito <The Ippolito Trust> - trustee and beneficiary of the trust 16,668,311 Fully Paid Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Director participation in Tranche 2 of the Placement, following shareholder approval granted at a general meeting held on 1 April 2026.

Part 2 – Change of director’s interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	Yes
If so, was prior written clearance provided to allow the trade to proceed during this period?	Yes. Subscription for shares under the Placement was approved by the Board and shareholders.
If prior written clearance was provided, on what date was this provided?	7 March 2026

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Botanix Pharmaceuticals Ltd
ABN	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Henry William Bosch
Date of last notice	3 December 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	10 April 2026
No. of securities held prior to change	18,836,702 Fully Paid Ordinary Shares 3,000,000 Performance Rights (expiring 2 December 2029)
Class	Fully Paid Ordinary Shares
Number acquired	1,666,667
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.06 per Fully Paid Ordinary Share
No. of securities held after change	20,503,369 Fully Paid Ordinary Shares 3,000,000 Performance Rights (expiring 2 December 2029)

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Director participation in Tranche 2 of the Placement, following shareholder approval granted at a general meeting held on 1 April 2026.
---	---

Part 2 – Change of director's interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	Yes
If so, was prior written clearance provided to allow the trade to proceed during this period?	Yes. Subscription for shares under the Placement was approved by the Board and shareholders.
If prior written clearance was provided, on what date was this provided?	7 March 2026

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Botanix Pharmaceuticals Ltd
ABN	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Daniel Sharp
Date of last notice	21 March 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	DJMB Corporate Pty Ltd - Mr Sharp is a director of DJMB Corporate Pty Ltd Mr Daniel Howard Sharp <Daniel H Sharp TT A/C> Mr Sharp is a trustee and a beneficiary
Date of change	10 April 2026
No. of securities held prior to change	DJMB Corporate Pty Ltd - Mr Sharp is a director of DJMB Corporate Pty Ltd 2,131,313 Fully Paid Ordinary Shares 4,000,000 Unlisted Options exercisable at 0.094 each, expiring 22 March 2025 333,333 Performance Rights (expiring 30 November 2026) 3,000,000 Performance Rights (expiring 2 December 2029)
Class	Fully Paid Ordinary Shares
Number acquired	833,333

+ See chapter 19 for defined terms.

Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.06 per Fully Paid Ordinary Share
No. of securities held after change	DJMB Corporate Pty Ltd - Mr Sharp is a director of DJMB Corporate Pty Ltd 2,131,313 Fully Paid Ordinary Shares 4,000,000 Unlisted Options exercisable at 0.094 each, expiring 22 March 2025 333,333 Performance Rights (expiring 30 November 2026) 3,000,000 Performance Rights (expiring 2 December 2029) Mr Daniel Howard Sharp <Daniel H Sharp TT A/C> Mr Sharp is a trustee and a beneficiary 833,333 Fully Paid Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Director participation in Tranche 2 of the Placement, following shareholder approval granted at a general meeting held on 1 April 2026.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A

+ See chapter 19 for defined terms.

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	Yes
If so, was prior written clearance provided to allow the trade to proceed during this period?	Yes. Subscription for shares under the Placement was approved by the Board and shareholders.
If prior written clearance was provided, on what date was this provided?	7 March 2026

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Botanix Pharmaceuticals Ltd
ABN	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Patricia Walker
Date of last notice	25 August 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (Including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	10 April 2026
No. of securities held prior to change	1,000,000 unquoted options exercisable at \$0.145, expiring on 22 August 2026 4,000,000 unquoted options exercisable at \$0.19, expiring on 22 August 2028 4,000,000 unquoted options exercisable at \$0.28, expiring on 12 July 2027
Class	Fully Paid Ordinary Shares
Number acquired	1,666,667
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.06 per Fully Paid Ordinary Share

+ See chapter 19 for defined terms.

No. of securities held after change	1,666,667 Fully Paid Ordinary Shares 1,000,000 unquoted options exercisable at \$0.145, expiring on 22 August 2026 4,000,000 unquoted options exercisable at \$0.19, expiring on 22 August 2028 4,000,000 unquoted options exercisable at \$0.28, expiring on 12 July 2027
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Director participation in Tranche 2 of the Placement, following shareholder approval granted at a general meeting held on 1 April 2026.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	Yes
If so, was prior written clearance provided to allow the trade to proceed during this period?	Yes. Subscription for shares under the Placement was approved by the Board and shareholders.
If prior written clearance was provided, on what date was this provided?	7 March 2026

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Botanix Pharmaceuticals Ltd
ABN	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Stewart Washer
Date of last notice	28 February 2026

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (Including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Dr Stewart James Washer + Dr Patrizia Derna Washer "<Washer Family S/Fund A/C>", - Dr Washer is a trustee and beneficiary of the trust.
Date of change	10 April 2026
No. of securities held prior to change	Dr Stewart James Washer + Dr Patrizia Derna Washer <The Washer Family A/C> - Dr Washer is a trustee and beneficiary of the trust. • 654,884 Fully Paid Ordinary Shares • 5,000,000 Unlisted Options exercisable at 0.102 each, expiring 22 March 2025 • 333,333 Performance Rights (expiring 30 November 2026) * • 3,000,000 Performance Rights (expiring 2 December 2029) Mal Washer Nominees Pty Ltd - Dr Washer is a Director. • 1,515,151 Fully Paid Ordinary Shares

+ See chapter 19 for defined terms.

Class	Fully Paid Ordinary Shares
Number acquired	1,666,667
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.06 per Fully Paid Ordinary Share
No. of securities held after change	Dr Stewart James Washer + Dr Patrizia Derna Washer <The Washer Family A/C> - Dr Washer is a trustee and beneficiary of the trust. • 654,884 Fully Paid Ordinary Shares • 5,000,000 Unlisted Options exercisable at 0.102 each, expiring 22 March 2025 • 333,333 Performance Rights (expiring 30 November 2026) * • 3,000,000 Performance Rights (expiring 2 December 2029) Mal Washer Nominees Pty Ltd - Dr Washer is a Director. • 1,515,151 Fully Paid Ordinary Shares Dr Stewart James Washer + Dr Patrizia Derna Washer <Washer Family S/ Fund A/C> - Dr Washer is a trustee and beneficiary of the trust. 1,666,667 Fully Paid Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Director participation in Tranche 2 of the Placement, following shareholder approval granted at a general meeting held on 1 April 2026.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A

+ See chapter 19 for defined terms.

Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	Yes
If so, was prior written clearance provided to allow the trade to proceed during this period?	Yes. Subscription for shares under the Placement was approved by the Board and shareholders.
If prior written clearance was provided, on what date was this provided?	7 March 2026

+ See chapter 19 for defined terms.